Buscar en
Enfermedades Infecciosas y Microbiología Clínica (English Edition)
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica (English Edition) Non-toxigenic Corynebacterium diphtheriae biotype belfanti in a diabetic patient...
Journal Information
Vol. 37. Issue 10.
Pages 680-681 (December 2019)
Vol. 37. Issue 10.
Pages 680-681 (December 2019)
Scientific letter
DOI: 10.1016/j.eimce.2018.10.016
Full text access
Non-toxigenic Corynebacterium diphtheriae biotype belfanti in a diabetic patient with upper tract respiratory infection
Corynebacterium diphtheriae biotipo belfanti no toxigénico en una paciente diabética con infección del tracto respiratorio superior
Visits
...
Laura Barradoa,
Corresponding author
ljbb550@msn.com

Corresponding author.
, Xabier Beristaina,b, Carmen Martín-Salasa,b, Carmen Ezpeleta-Baquedanoa,b
a Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
b Servicio de Microbiología Clínica, Complejo Hospitalario de Navarra, Pamplona, Spain
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Full Text

This case discusses a 77-year-old woman who went to her primary care doctor with a sore throat, cough, drowsiness, greenish sputum and afebrile (36.7°C). She presented as history of interest diabetes mellitus secondary to steroid treatment and bronchiectasis. Her recent vaccination record included the flu vaccine and tetanus–diphtheria vaccine, which was administered in 2003. She had no history of contact with animals or recent travel. A sample of sputum was collected for culture and abundant leukocytes and Gram-positive bacilli were observed in the Gram stain (Fig. 1). After 24h of incubation, in Columbia CNA agar with 5% sheep blood and chocolate agar, very small pure colonies were isolated in culture (∼1mm diameter), catalase-positive, grey and shiny with a small area of beta-haemolysis. The microorganism was identified as Corynebacterium diphtheriae (C. diphtheriae) biotype mitis/belfanti using API Coryne (bioMérieux; BioNumber 0000324; 90.2%) and MALDI-TOF (MALDI Biotyper® Microflex LT, Bruker Daltonik GmbH; score: 1786). The gene coding for subunit β of RNA polymerase (rpoB) was sequenced, confirming this identification.1 The presence of the diphtheria toxin gene (tox) was not detected using PCR2 and its expression was not detected either using the Elek test.3 Antimicrobial susceptibility was determined using the ɛ-test method (bioMérieux) and interpreted according to the recommendations established by the Clinical & Laboratory Standards Institute [CLSI] (www.clsi.org). The minimum inhibitory concentrations (μg/ml) were: penicillin (0.25, susceptible [S]), cefotaxime (1.5, intermediate [I]), cefepime (1.5, I), imipenem (0.125, S), meropenem (0.064, S), erythromycin (0.016, S), ciprofloxacin (>32, resistant), tetracycline (0.75, S), clindamycin (0.25, S), co-trimoxazole (0.064, S), rifampicin (0.002, S), and linezolid (0.25, S). Antibiotic treatment was also established with erythromycin 500mg/day for 14 days with favourable progression.

Fig. 1.

Gram stain of sputum (1000×) in which abundant leukocytes and Gram-positive bacilli of Corynebacteriaceae morphology can be observed.

(0.15MB).

Since 1986, three articles have been published in Spain on respiratory and cutaneous diphtheria due to toxigenic and/or non-toxigenic (NT) strains.4–6 This is the first documented case of respiratory diphtheria caused by biotype belfanti NT in Spain. The main reservoir of C. diphtheriae is humans. However, both types of strains have been isolated in domestic, and even wild, animals with no evidence of zoonotic transmission.7

C. diphtheriae is made up of four biotypes: gravis, mitis, intermedius, and belfanti. The biotype belfanti presents respiratory tropism taking advantage at the time of colonising or infecting the upper respiratory tract compared to other biotypes, being described fundamentally in cases of primary chronic atrophic rhinitis (ozaena).8 It has been isolated most frequently in geographic areas with a high vaccine coverage, such as North America and Europe (36–100%). During the post-epidemic period, its presence has been increasing in Europe replacing the toxigenic strains, which belong mostly to the biotypes gravis and mitis.9,10 The NT strains can cause severe infections such as myocarditis, endocarditis, bacteraemia, septic arthritis, osteomyelitis, neuritis and epiglottitis.8–10 Its mechanism of pathogenicity is still not understood and little is known about the genes responsible for colonisation, invasion and survival in the host, as well as about other virulence factors aside from the production of the toxin.

MALDI-TOF has been described as a useful, cost-effective and rapid tool for the identification of this microorganism along with other toxigenic species such as Corynebacterium ulcerans and Corynebacterium pseudotuberculosis, although it is not able to differentiate toxigenic strains from NT stains.11 In addition, the sequencing of the gene rpoB has demonstrated greater discriminatory power (91%) than the sequencing of 16S rRNA (81%).12 These methods should always be accompanied by the detection and expression of the tox gene, with the absence of diphtheria toxin being something common in the biotype belfanti, which has demonstrated great clonal diversity compared to the other biotypes.9,10

Over the years, an increase in the antimicrobial resistance of NT strains has been observed. C. diphtheriae biotype belfanti tends to present greater susceptibility than the other biotypes. However, reduced susceptibility to ciprofloxacin, cefotaxime and cefepime has been reported. These are not considered to be good treatment options. Erythromycin or penicillin are the treatment of choice, with both not being effective in some cases due to the description of resistant strains.8–10

This case demonstrates the need to monitor the spreading of C. diphtheriae strains circulating in Spain; not only those strains which are toxigenic, but also the NT strains which should be considered emerging pathogens.

Acknowledgements

The authors would like to thank Silvia Herrera León from the Spanish National Microbiology Centre of Majadahonda (ISCIII) for carrying out the characterisation of the isolation.

References
[1]
A. Khamis, D. Raoult, B. la Scola.
rpoB gene sequencing for identification of Corynebacterium species.
J Clin Microbiol, 42 (2004), pp. 3925-3931
[2]
E.A. Mothershed, P.K. Cassiday, K. Pierson, L.W. Mayer, T. Popovic.
Development of a real-time fluorescence PCR assay for rapid detection of the diphtheria toxin gene.
J Clin Microbiol, 40 (2002), pp. 4713-4719
[3]
K.H. Engler, T. Glushkevich, I.K. Mazurova, R.C. George, A. Efstratiou.
A modified Elek test for detection of toxigenic corynebacteria in the diagnostic laboratory.
J Clin Microbiol, 35 (1997), pp. 495-498
[4]
D. Morgado-Carrasco, C. Riquelme-Mc Loughlin, X. Fustá-Novell, M.J. Fernández-Pittol, J. Bosch, J.M. Mascaró Jr..
Cutaneous diphtheria mimicking pyoderma gangrenosum.
JAMA Dermatol, 154 (2018), pp. 227-228
[5]
M.E. Sánchez, J.B. Álvarez, S.H. León.
Chronic nonhealing ulcerated nodules in a Spanish boy after traveling.
JAMA Dermatol, 151 (2015), pp. 1247-1248
[6]
M. Jané, M.J. Vidal, N. Camps, M. Campins, A. Martínez, J. Balcells, et al.
A case of respiratory toxigenic diphtheria: contact tracing results and considerations following a 30-year disease-free interval, Catalonia, Spain, 2015.
Euro Surveill, 23 (2018),
[7]
A. Sing, R. Konrad, D.M. Meinel, N. Mauder, I. Schwabe, R. Sting.
Corynebacterium diphtheriae in a free-roaming red fox: case report and historical review on diphtheria in animals.
Infection, 44 (2016), pp. 441-445
[8]
N. Benamrouche, S. Hasnaoui, E. Badell, B. Guettou, M. Lazri, N. Guiso, et al.
Microbiological and molecular characterization of Corynebacterium diphtheriae isolated in Algeria between 1992 and 2015.
Clin Microbiol Infect, 22 (2016), pp. 1005
[9]
U. Czajka, A. Wiatrzyk, E. Mosiej, K. Formińska, A.A. Zasada.
Changes in MLST profiles and biotypes of Corynebacterium diphtheriae isolates from the diphtheria outbreak period to the period of invasive infections caused by nontoxigenic strains in Poland (1950–2016).
BMC Infect Dis, 18 (2018), pp. 121
[10]
E. Farfour, E. Badell, S. Dinu, S. Guillot, N. Guiso.
Microbiological changes and diversity in autochthonous non-toxigenic Corynebacterium diphtheriae isolated in France.
Clin Microbiol Infect, 19 (2013), pp. 980-987
[11]
S.K. Rajamani Sekar, B. Veeraraghavan, S. Anandan, N.K. Devanga Ragupathi, L. Sangal, S. Joshi.
Strengthening the laboratory diagnosis of pathogenic Corynebacterium species in the Vaccine era.
Lett Appl Microbiol, 65 (2017), pp. 354-365
[12]
A. Khamis, D. Raoult, B. La Scola.
Comparison between rpoB and 16S rRNA gene sequencing for molecular identification of 168 clinical isolates of Corynebacterium.
J Clin Microbiol, 43 (2005), pp. 1934-1936

Please cite this article as: Barrado L, Beristain X, Martín-Salas C, Ezpeleta-Baquedano C. Corynebacterium diphtheriae biotipo belfanti no toxigénico en una paciente diabética con infección del tracto respiratorio superior. Enferm Infecc Microbiol Clin. 2019. https://doi.org/10.1016/j.eimc.2018.10.005

Copyright © 2018. Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.